Updated version 1 - With trading delays easing, IBM raises annual software revenue expectations.
路透社2026/10/21 20:23Add stock price trend
Anhata Rooprai
Reuters, October 21 - IBM IBM.N Chief Financial Officer James Kavanaugh said on Wednesday that the delayed software deals which unsettled investors last quarter are now beginning to close. Meanwhile, the company raised its performance outlook for the segment and reported third-quarter results that beat expectations.
Kavanaugh told Reuters in an interview that IBM now expects annual software revenue growth of about 7% to 8%, higher than the previously expected 6% to 8%. IBM shares rose about 4% in after-hours trading.
Here are more details:
According to data compiled by LSEG, third-quarter revenue grew 4.7% to $17.1 billion, beating the average analyst forecast of $16.82 billion.
Adjusted earnings per share were $2.95, higher than the market expectation of $2.86.
CEO Arvind Krishna said in July that IBM had “not performed well” in adapting to a shift in customer spending from software to data center infrastructure (link), which triggered the company's steepest single-day share price drop in over a century.
Third-quarter software revenue grew 8.3% to $7.8 billion, surpassing the expected $7.62 billion.
Within this segment, sales in the hybrid cloud unit rose 11%, and transaction processing software revenue rose 9%, rebounding from last quarter’s unexpected decline.
Kavanaugh said about 25% of transaction processing revenue came from deals delayed in the second quarter, while “the remaining 75% is net new business.”
Infrastructure segment revenue rose 4.2% to $3.71 billion, with 31% growth in distributed infrastructure, including servers and storage systems, helping offset weakness in the Z mainframe business.
https://www.reuters.com/graphics/IBM-RESULTS/STOCK/xmvjwylqdpr/chart.png
(To accommodate non-English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translated text, which is provided for convenience only. Reuters assumes no responsibility for any damage or loss arising from use of the automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tom Lee Says Yields Below 5% Mean the AI Selloff Is Nearly Over
Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.
Lycia will issue 17.64 million shares at a price of $18 per share to raise $317.5 million.
Citi is bullish on Palantir (PLTR.US): U.S. government and commercial businesses jointly drive growth, Q3 revenue is expected to exceed expectations again
Citigroup maintains its "Buy" rating on Palantir and raises the target price from $245 to $250.
Despite its stock price being halved, Goldman Sachs maintains a Buy rating: Holding $10 billions in orders, CoreWeave (CRWV) faces a major test with several billions in financing
As a core manufacturer of AI computing power infrastructure, CoreWeave (CRWV.US) holds orders worth tens of billions and its business is expanding rapidly. However, capital expenditure pressure and financing gaps have become the main concerns of the market.
Crypto prices
More
